Intrathecal immune reactivity against Measles-, Rubella-, and Varicella Zoster viruses is associated with cerebrospinal fluid inflammation in multiple sclerosis.

Antibodies Rubella virus/immunology* biomarkers/cerebrospinal fluid herpesvirus 3 human/immunology* humans measles virus/immunology* multiple sclerosis/cerebrospinal fluid* multiple sclerosis/virology viral/cerebrospinal fluid*

Journal

Multiple sclerosis (Houndmills, Basingstoke, England)
ISSN: 1477-0970
Titre abrégé: Mult Scler
Pays: England
ID NLM: 9509185

Informations de publication

Date de publication:
08 Oct 2024
Historique:
medline: 8 10 2024
pubmed: 8 10 2024
entrez: 8 10 2024
Statut: aheadofprint

Résumé

We aimed to determine in multiple sclerosis (MS) whether intrathecal immunoglobulin G (IgG) production against measles- (M), rubella- (R), and varicella zoster (Z) viruses, which is called MRZ reaction (MRZR) and considered the most specific soluble biomarker for MS, is associated with demographic and basic cerebrospinal fluid (CSF) parameters reflecting inflammation. We analyzed the presence of positive MRZR and associations with demographic and clinical routine CSF parameters in 513 patients with MS and 182 non-MS patients. Comparing MS patients versus non-MS patients, positive MRZR (38.8% versus 2.2%; specificity 97.8%; positive likelihood ratio, PLR 17.7) had a better specificity and PLR for MS than CSF-specific OCB (89.5% versus 22.0%; specificity 78.0%; PLR 4.1). A positive MRZR in MS patients was associated with female sex ( This study confirms the MRZR as a highly specific marker of MS and shows that MRZR-positive MS patients more frequently are female and show inflammatory changes of basic CSF parameters than MRZR-negative MS patients.

Sections du résumé

BACKGROUND/OBJECTIVES UNASSIGNED
We aimed to determine in multiple sclerosis (MS) whether intrathecal immunoglobulin G (IgG) production against measles- (M), rubella- (R), and varicella zoster (Z) viruses, which is called MRZ reaction (MRZR) and considered the most specific soluble biomarker for MS, is associated with demographic and basic cerebrospinal fluid (CSF) parameters reflecting inflammation.
METHODS UNASSIGNED
We analyzed the presence of positive MRZR and associations with demographic and clinical routine CSF parameters in 513 patients with MS and 182 non-MS patients.
RESULTS UNASSIGNED
Comparing MS patients versus non-MS patients, positive MRZR (38.8% versus 2.2%; specificity 97.8%; positive likelihood ratio, PLR 17.7) had a better specificity and PLR for MS than CSF-specific OCB (89.5% versus 22.0%; specificity 78.0%; PLR 4.1). A positive MRZR in MS patients was associated with female sex (
CONCLUSIONS UNASSIGNED
This study confirms the MRZR as a highly specific marker of MS and shows that MRZR-positive MS patients more frequently are female and show inflammatory changes of basic CSF parameters than MRZR-negative MS patients.

Identifiants

pubmed: 39377663
doi: 10.1177/13524585241279645
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

13524585241279645

Déclaration de conflit d'intérêts

Declaration of Conflicting InterestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: R.M. is employed part-time by Cellerys, a startup company outfounded from the University of Zurich. He is a co-founder and stockholder of Cellerys and a co-founder of Abata Therapeutics. R.M. is listed as an inventor on patents of the University of Zurich about target antigens in multiple sclerosis. R.M. is further listed as an inventor and received remuneration for an NIH-held patent on the use of daclizumab to treat multiple sclerosis. None of which has an impact on the submitted work. I.J. has received speaker honoraria or unrestricted grants from Biogen Idec and Novartis and has received compensation for advice or lecturing by Alexion, Biogen, Bristol Myers Squibb, Celgene, Janssen-Cilag, Neuway, Merck, Novartis, Roche, and Sanofi Genzyme; none of these are related to this study. The other authors report no conflicts of interest related to this work.

Auteurs

Benjamin Vlad (B)

Neuroimmunology and Multiple Sclerosis Research Section, Department of Neurology, University of Zurich and University Hospital, Zurich, Switzerland.

Stephan Neidhart (S)

Neuroimmunology and Multiple Sclerosis Research Section, Department of Neurology, University of Zurich and University Hospital, Zurich, Switzerland; Swiss Epilepsy Center (Klinik Lengg), Zurich, Switzerland.

Marc Hilty (M)

Neuroimmunology and Multiple Sclerosis Research Section, Department of Neurology, University of Zurich and University Hospital, Zurich, Switzerland.
Department of Neurology, Hirslanden Klinik Zurich, Zurich, Switzerland.

Klara Asplund Högelin (K)

Center for Molecular Medicine, Neuroimmunology Unit, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.

Ina Reichen (I)

Neuroimmunology and Multiple Sclerosis Research Section, Department of Neurology, University of Zurich and University Hospital, Zurich, Switzerland.
Neuroimmunology Outpatient Clinic, Center for Multiple Sclerosis, Neurocenter Bellevue, Zurich, Switzerland.

Mario Ziegler (M)

Neuroimmunology and Multiple Sclerosis Research Section, Department of Neurology, University of Zurich and University Hospital, Zurich, Switzerland.

Mohsen Khademi (M)

Center for Molecular Medicine, Neuroimmunology Unit, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.

Andreas Lutterotti (A)

Neuroimmunology and Multiple Sclerosis Research Section, Department of Neurology, University of Zurich and University Hospital, Zurich, Switzerland.
Clinical Research Priority Program MS (CRPP), PrecisionMS of the University of Zurich, Zurich, Switzerland.
Neuroimmunology Outpatient Clinic, Center for Multiple Sclerosis, Neurocenter Bellevue, Zurich, Switzerland.

Axel Regeniter (A)

Infectious Disease Serology and Immunology, Medica Medizinische Laboratorien Dr. F. Kaeppeli AG, Zurich, Switzerland.

Roland Martin (R)

Neuroimmunology and Multiple Sclerosis Research Section, Department of Neurology, University of Zurich and University Hospital, Zurich, Switzerland.
Clinical Research Priority Program MS (CRPP), PrecisionMS of the University of Zurich, Zurich, Switzerland.
Center for Molecular Medicine, Therapeutic Immune Design Unit, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.

Faiez Al Nimer (F)

Center for Molecular Medicine, Neuroimmunology Unit, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.

Ilijas Jelcic (I)

Neuroimmunology and Multiple Sclerosis Research Section, Department of Neurology, University of Zurich and University Hospital, Zurich, Switzerland.
Clinical Research Priority Program MS (CRPP), PrecisionMS of the University of Zurich, Zurich, Switzerland.
Neuroimmunology Outpatient Clinic, Center for Multiple Sclerosis, Neurocenter Bellevue, Zurich, Switzerland.

Classifications MeSH